Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 4,455 articles

Articles by Daniel Marsh

10x Genomics Tumbles on Revenue Slide; Buffett Warns of 'Gambling Mood'
Markets

10x Genomics Tumbles on Revenue Slide; Buffett Warns of 'Gambling Mood'

10x Genomics shares dropped 5.3% after Q1 revenue fell 2.6% year-over-year, while Warren Buffett cautioned investors against a 'gambling mood' driving unsustainable valuations.

TXG SPY BRK.B TMO BABA FXI GLD SLV USO UNG
Stocks Dip as Oil Surge Fuels Inflation Fears, Fed Cut Hopes Fade
Markets

Stocks Dip as Oil Surge Fuels Inflation Fears, Fed Cut Hopes Fade

US stocks retreated Tuesday as a hotter-than-expected April CPI report and surging oil prices dampened rate-cut expectations, with tech and chip stocks leading declines.

QCOM INTC MU NVDA HUM ZBRA GME HIMS UA
SELLAS Stock Surges as REGAL Trial Nears Final Analysis
Analysis

SELLAS Stock Surges as REGAL Trial Nears Final Analysis

SELLAS Life Sciences shares rose after hours as its REGAL leukemia trial recorded 78 of 80 events needed for final analysis. The company reported a Q1 net loss of $8.4 million but has $107.1 million in cash.

SLS
Tesla Stock Drops on Sticky Inflation and Robotaxi Hiccups
Markets

Tesla Stock Drops on Sticky Inflation and Robotaxi Hiccups

Tesla shares fell 2.7% to $433.45 after hot inflation data and reports of long waits for its robotaxi service in Texas, testing investor confidence in the AI premium.

TSLA GOOGL GM F RIVN
Ernexa Therapeutics Soars 58% on Ovarian Cancer Therapy Hopes
Markets

Ernexa Therapeutics Soars 58% on Ovarian Cancer Therapy Hopes

Ernexa Therapeutics surged 58.5% on Tuesday after renewed investor interest in its preclinical ovarian-cancer cell therapy ERNA-101, though funding concerns persist.

ERNA
Byron Allen's $120M Bet Revives BuzzFeed Stock, But Turnaround Uncertain
Markets

Byron Allen's $120M Bet Revives BuzzFeed Stock, But Turnaround Uncertain

BuzzFeed shares nearly doubled after Byron Allen's family office agreed to buy a controlling stake, but the deal is mostly debt and the company still faces a going concern warning.

BZFD
Dow Holds Steady at 49,700 as Inflation Data Rattles Tech and Rate Outlook
Markets

Dow Holds Steady at 49,700 as Inflation Data Rattles Tech and Rate Outlook

The Dow ended nearly unchanged at 49,700.29, but the S&P 500 dropped 0.54% and the Nasdaq fell 1.37% after April CPI surged 3.8%, driven by energy costs.

DIA SPY QQQ USO GLD UNH KO WMT VZ JPM SAP IBM AMZN CAT MSFT INTC MU CVX XOM
Markets

Inflation and Oil Surge Halt Wall Street Rally

Hotter-than-expected inflation and surging oil prices ended Wall Street's record run. The S&P 500 fell 0.4% and the Nasdaq dropped 1.2%, with chip stocks like Intel and Micron leading declines.

INTC MU CVX USO SPY QQQ DIA XLK XLE
Berkshire's Cash Pile Shines as Inflation Fuels Investor Demand
Markets

Berkshire's Cash Pile Shines as Inflation Fuels Investor Demand

Berkshire Hathaway's Class B shares gained 1.4% Tuesday, driven by inflation data that highlights the value of its massive cash and short-term Treasury position.

BRK.B SPY CB PGR UNP GLD
Venture Global Soars 16% on Strong 2026 Guidance and New LNG Deals
Markets

Venture Global Soars 16% on Strong 2026 Guidance and New LNG Deals

Venture Global shares jumped 16% after the company boosted its 2026 earnings guidance and announced new LNG supply agreements with TotalEnergies and Vitol.

VG TTE CVX UNP GLNG XOM
Merck Closes $53/Share Acquisition of Terns Pharmaceuticals, Stock Ceases Trading
Markets

Merck Closes $53/Share Acquisition of Terns Pharmaceuticals, Stock Ceases Trading

Merck has finalized its $53-per-share cash acquisition of Terns Pharmaceuticals, causing Terns stock to stop trading on Nasdaq. The deal values Terns at $6.7 billion.

MRK TERN
Archer Aviation Sinks on Cash Burn Concerns Despite FAA Progress
Markets

Archer Aviation Sinks on Cash Burn Concerns Despite FAA Progress

Archer Aviation shares dropped 6.6% despite an FAA milestone, as investors focused on the company's $217.7 million net loss and $188.8 million cash burn.

ACHR JOBY